首页> 美国卫生研究院文献>American Journal of Public Hygiene >Evolution and Convergence of State Laws Governing Controlled Substance Prescription Monitoring Programs 1998-2011
【2h】

Evolution and Convergence of State Laws Governing Controlled Substance Prescription Monitoring Programs 1998-2011

机译:1998-2011年关于管制药物处方监控程序的州法律的演变和趋同

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives. We sought to collect and characterize all laws governing the operation of prescription monitoring programs (PMPs), state-level databases that collect patient-specific prescription information, which have been suggested as a tool for reducing prescription drug overdose fatalities.Methods. We utilized a structured legal research protocol to systematically identify, review, and code all PMP statutes and regulations effective from 1998 through 2011. These laws were then abstracted along eleven domains, including reporting provisions, data sharing, and data access.Results. PMP characteristics vary greatly among states and across time. We observed an increase in the types and frequency of data required to be reported, the types of individuals permitted to access PMP data, and the percentage of PMPs authorized to proactively identify outlier prescribers and patients. As of 2011, 10 states required PMPs to report suspicious activity to law enforcement, while only 3 required reporting to the patient’s physician. None required linkage to drug treatment or required all prescribers to review PMP data before prescribing. Few explicitly address data retention.Conclusions. State PMP laws are heterogeneous and evolving. Future studies of PMP effectiveness should take these variations into account.
机译:目标。我们试图收集并描述所有有关处方监测程序(PMP)运作的法律,这些法律是收集患者特定处方信息的州级数据库,已被建议作为减少处方药过量死亡的工具。我们利用结构化的法律研究协议来系统地识别,审查和编码从1998年到2011年生效的所有PMP法规。然后,这些法律从11个领域中抽象出来,包括报告条款,数据共享和数据访问。各州之间以及整个时间之间,PMP的特性差异很大。我们观察到,需要报告的数据类型和频率,允许访问PMP数据的个人类型以及被授权主动识别异常处方者和患者的PMP百分比均在增加。截至2011年,有10个州要求PMP向执法部门报告可疑活动,而只有3个要求向患者的医生报告。没有人需要与药物治疗相关联,也不需要所有开处方的人在开药前检查PMP数据。很少有明确涉及数据保留的问题。州PMP法律是异类且不断发展的。 PMP有效性的未来研究应考虑这些差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号